No existe incremento de incidencia y recurrencia de cáncer de mama en pacientes tratadas con ospemifeno con atrofia vulvovaginal (AVV)
To improve your experience, this website uses cookies for analytics and functionality purposes. More information about how we use cookies and how you can control them is in our Cookie Policy. By continuing to use our website you agree to our use of these cookies.
